Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenues	$ 1,362	$ 565	$ 3,764	$ 1,775
Cost of revenues	1,608	779	4,256	2,100
Gross profit/(loss)	(246)	(214)	(492)	(325)
Operating expenses:
Sales and marketing	4,594	1,976	10,973	3,872
Research and development	1,618	757	3,380	1,847
General and administrative	2,939	3,212	10,980	6,446
Total operating expenses	9,151	5,945	25,333	12,165
Loss from operations	(9,397)	(6,159)	(25,825)	(12,490)
Other expense:
Gain on debt extinguishment		928		928
Interest income/(expense)	9	(364)	19	(2,657)
Other expense		(131)		(355)
Total other income/(expense)	9	433	19	(2,084)
Net loss	$ (9,388)	$ (5,726)	$ (25,806)	$ (14,574)
Weighted average shares outstanding used in computing net loss per share, basic and diluted	18,928,418	7,134,642	16,069,989	5,331,876
Net loss per share of common stock outstanding, basic and diluted	$ (0.50)	$ (0.80)	$ (1.61)	$ (2.73)
Assay Revenue
Revenues:
Total revenues	$ 1,233	$ 385	$ 2,678	$ 905
Contract Revenue
Revenues:
Total revenues	$ 129	$ 180	$ 1,086	$ 870